Chemotherapy-driven dysbiosis in the intestinal microbiome.
about
How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future DirectionsIdentifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection.Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection.The gut microbiota and gastrointestinal surgery.Gut microbiota modulation of chemotherapy efficacy and toxicity.Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients.Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients.Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation.Fecal microbiota transplantation-early steps on a long journey ahead.New Options in Constipation Management.Colonization and infection with extended-spectrum beta-lactamase producing Enterobacteriaceae in patients with malignancy.Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice.Gut microbiota composition associated with alterations in cardiorespiratory fitness and psychosocial outcomes among breast cancer survivors.Sensing danger: toll-like receptors and outcome in allogeneic hematopoietic stem cell transplantation.Microbiota: a key orchestrator of cancer therapy.The role of the microbiome in cancer development and therapy.Fecal Microbiota Transplantation Inhibits Multidrug-Resistant Gut Pathogens: Preliminary Report Performed in an Immunocompromised Host.5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro.Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications.The gut microbiome, symptoms, and targeted interventions in children with cancer: a systematic review.Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study.Evaluation of bloodstream infections, Clostridium difficile infections, and gut microbiota in pediatric oncology patients.Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses.Animal models of chemotherapy-induced mucositis: translational relevance and challenges.Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut dysbiosis in mice.Gut Microbiome Composition Predicts Infection Risk during Chemotherapy in Children with Acute Lymphoblastic Leukemia.Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis.Pre-, pro- and synbiotics in cancer prevention and treatment-a review of basic and clinical research
P2860
Q26771113-CED0D2E5-E8A4-48B3-9666-5EB8FF5C7FABQ33874148-8E0918DD-CC57-4F2E-9FE0-692C45D79416Q36001287-C9395BAC-DB5F-455F-914F-3A8034FFFD5AQ36018079-40F4DD67-0FCF-4355-95C0-59F2474F66EAQ36161048-644C57FD-6449-4C64-B9DB-71D07EAEA488Q36300217-96C67DDE-84F2-4463-A9CC-A4DF9766F33EQ37166564-54E1AB60-41E4-4B6E-A4CA-CEF8E0A91660Q37673349-C2858CD7-8B82-4812-97AF-BFF0F4CC4B51Q37713517-F4BC80F0-F47C-46FB-BD31-16163508BF01Q38557914-3535FAB9-A1BE-48F6-87D7-6EBC41E789FCQ38602701-90AC585A-11D5-4FEA-A89C-EA67826C19FDQ38665505-B0AFD3FB-68C9-4231-8878-CD2DB1750D35Q38856557-337B61C7-DEB9-4E2E-BCF1-DCECBACAF0DAQ39033818-2A7A74E9-9337-4D03-863F-79581F67B9D9Q39035928-1F30F28F-240D-4FDA-9B9B-BCC825D72DB1Q39183428-0220636A-7BBB-4AE1-B6DC-4A9162C4FA58Q39290620-A53F42D1-7901-472F-9BE5-4110FE4CDB2FQ42796168-4474EC3B-87FC-44E0-9B03-8753878876F4Q46257516-228570EE-A8C8-407B-AB20-DA2E44EE5B20Q47283908-653F63AA-579E-4820-9FA9-7B707781AD47Q47425267-0E9D774F-951E-4E54-91AE-99750B39C7F7Q47580986-296C6900-2DBF-4880-A548-38A08A67B897Q48252572-BB765538-33D4-4B3D-8181-A3B3C0A2F4FCQ48313696-462D93A9-78FA-443B-8507-E35F94E224B9Q50091831-51356160-5DB0-42E5-9185-38B8FE620D49Q52691475-64D5A84F-01AE-4DA4-99DD-625B9881CC6DQ54259784-CAB14196-CB59-489B-A959-4CDE7BD555B6Q55040688-C50DF164-EA63-4384-95F0-B7216D6E1EBEQ55553797-0EAAF993-447C-4510-BFAF-35FCFA01BB7BQ58762646-31F29501-04F0-4F18-98BC-65EE8CDCF615
P2860
Chemotherapy-driven dysbiosis in the intestinal microbiome.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Chemotherapy-driven dysbiosis in the intestinal microbiome.
@ast
Chemotherapy-driven dysbiosis in the intestinal microbiome.
@en
type
label
Chemotherapy-driven dysbiosis in the intestinal microbiome.
@ast
Chemotherapy-driven dysbiosis in the intestinal microbiome.
@en
prefLabel
Chemotherapy-driven dysbiosis in the intestinal microbiome.
@ast
Chemotherapy-driven dysbiosis in the intestinal microbiome.
@en
P2093
P2860
P356
P1476
Chemotherapy-driven dysbiosis in the intestinal microbiome
@en
P2093
E Montassier
G A Al-Ghalith
M F de La Cochetière
S Bruley des Varannes
T Gastinne
P2860
P304
P356
10.1111/APT.13302
P407
P50
P577
2015-07-06T00:00:00Z